Latanoprost Yonsung (Latanoprost)

Latanoprost acts as a prostaglandin F‑type receptor agonist. Binding to FP receptors in the ciliary body triggers remodeling of the extracellular matrix, which enhances uveoscleral outflow of aqueous humor. The increased drainage lowers intraocular pressure, providing therapeutic benefit in glaucoma and related disorders.

The specific dosing regimen is determined by the prescribing clinician. In practice, latanoprost is commonly administered as one drop in the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally provides greater intraocular pressure reduction than beta‑blockers such as timolol. Compared with other prostaglandin analogs (e.g., bimatoprost, travoprost), latanoprost has a similar efficacy profile but may differ slightly in side‑effect frequency, such as iris pigmentation changes.

The solution should be stored at room temperature, below 25 °C, in its original container. Protect it from light and moisture, and keep the bottle tightly closed when not in use. Do not freeze the product; discard any solution that appears discolored or contains particles.

Latanoprost Yonsung is applied topically to the eye. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac of the affected eye(s). The eye should be closed gently for a few seconds to enhance absorption.

Serious adverse events, although rare, include severe ocular inflammation (uveitis or iritis), allergic reactions with swelling or rash, sudden vision loss, and corneal ulceration. Patients should seek immediate medical attention if they experience intense eye pain, marked vision changes, or signs of an allergic response.

Latanoprost is contraindicated in individuals with known hypersensitivity to latanoprost or any component of the formulation. It should also be avoided in patients with active ocular infections or inflammation until those conditions are resolved. Pregnant or breastfeeding women should only use it if the prescriber determines the benefits outweigh potential risks.